FEB 0 5 2007 W FEB 0 5 2007 W SUITE 300 GARDEN CITY, NY 11530

### SCULLY, SCOTT, MURPHY & PRESSER PC

INTELLECTUAL PROPERTY LAW

January 19, 2007

LEOPOLD PRESSER FRANK S. DIGIGLIO PAUL J. ESATTO, JR. JOHN S. SENSNY MARK J. COHEN EDWARD W. GROLZ STEVEN FISCHMAN PETER I. BERNSTEIN THOMAS SPINELLI XIAOCHUN ZHU

516-742-4343 FAX: 516-742-4366 E-MAIL: INTPROP@SSMP.COM WWW.SSMP.COM

ROBERT L. BERNSTEIN
MARVIN BRESSLER
DERMOTT J. COOKE®
RICHARD J. DANYKO
BRADLEY M. MARAZAS
KATHERINE R. VIEYRA®
SETH M. WEINFELD
KEITH A. WELTSCH®
YONGZHI YANG®

PATENT AGENTS
LESLIE S. SZIVOS,PHD
DAVID J. TORRENTE, J.D.
ZHUANG YUAN

COUNSEL
BOSCO B. KIM
BARRY M. KRIVISKY
ALLEN R. MORGANSTERN
ALEK P. SZECSY
STEPHEN A. YOUNG

TECHNICAL CONSULTANTS

DOMINICK A. TUCCIO

RETIRED
JOHN F. SCULLY
STEPHEN D. MURPHY

ANTHONY C. SCOTT 1931-1994

OH BAR ONLY
MD BAR ONLY
ONC BAR ONLY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re:

USSN: 10/551,352

Gail Petuna Risbridger, et al.

Our Docket: 19215

Dear Sirs:

The Filing Receipt for the above-identified patent application does not list the Assignment for Published Patent Application information. It should read as follows:

Assignment for Published Patent Application Prostate Diagnostics Pty. Ltd. Clayton, Victoria, Australia The Leland Stanford Junior University, Stanford Californa

as indicated on the enclosed pages. Please make the corrections and send us a corrected Filing Receipt.

SSM&P/tw Encl.



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. DOI 1450 Alexandra, Viginia 22313-1450

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/551,352	10/04/2006	1645	2990	19215	11	30	5

**CONFIRMATION NO. 6430** 

FILING RECEIPT

\*OC00000021087766\*

23389 SCULLY SCOTT MURPHY & PRESSER, PC 400 GARDEN CITY PLAZA SUITE 300 GARDEN CITY, NY 11530

Date Mailed: 11/07/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Gail Petuna Risbridger, Victoria, AUSTRALIA; Donna M Peehl, Mountain View, CA; Sally Louise Mellor, Victoria, AUSTRALIA; Emma Margaret Anne Ball, Victoria, AUSTRALIA;

Power of Attorney: The patent practitioners associated with Customer Number 23389.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/AU04/00389 03/29/2004 which claims benefit of 60/457,939 03/28/2003

Foreign Applications

If Required, Foreign Filing License Granted: 11/02/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/551,352

Projected Publication Date: 02/08/2007

Non-Publication Request: No

Early Publication Request: No

Title

Diagnosis of advanced cancer

**Preliminary Class** 

435

# PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

٠		ATTORNE; "S DOCKET NUMBER							
FORM P	TO-1390 2005)	(Modified) U.S. PATERI AND TRACEMENTS THE							
	TRA	NSMITTAL LETTER IC THE UNITED STATES							
	D	ESIGNATED/ELECTED OFFICE (DO/EO/US)  U.S. APPLICATION NO. (If known, see 37 CFR 1.5)							
С	ONO	CERNING A SUBMISSION UNDER 35 U.S.C. 371							
	NATIO	ONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED							
	PC	T/AU2004/000389 29 Watch 2004(25,03.2004) 25 Watch 2005							
TITLE DIAG	DIAGNOSIS OF ADVANCED CANCER  FEB 0 5 2007								
APPL	ICANT	(S) FOR DO/EO/US							
Gail l	Petuna	Risbridger, Donna M. Peehl, Sally Louise Melogand Pargaret Anne Ball							
		TO TO U.O. the fall wine in the condition information:							
Applic	ant he	rewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:							
1.	$\boxtimes$	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.							
2.		This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.							
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.							
4.	. $\square$	The US has been elected (Article 31).							
5.	$\boxtimes$	A copy of the International Application as filed (35 U.S.C. 371 (c)(2))							
ļ		a.  is attached hereto (required only if not communicated by the International Bureau).							
		b. 🛛 has been communicated by the International Bureau.							
1		c.  is not required, as the application was filed in the United States Receiving Office (RO/US).							
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).							
		a.  is attached hereto.							
		b. has been previously submitted under 35 U.S.C. 154(d)(4).							
7.	$\boxtimes$	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))							
i		a.   are attached hereto (required only if not communicated by the International Bureau).							
Ì		b.  have been communicated by the International Bureau.							
		c.  have not been made; however, the time limit for making such amendments has NOT expired.							
Į.		d. 🖾 have not been made and will not be made.							
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).							
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).							
11.		A copy of the International Preliminary Examination Report (PCT/IPEA/409).							
12.	×	A copy of the International Search Report (PCT/ISA/210).							
i	tems '	3 to 23 below concern document(s) or information included:							
13.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
15.	$\boxtimes$	A FIRST preliminary amendment.							
16.		A SECOND or SUBSEQUENT preliminary amendment.							
17.		A substitute specification.							
18.		A power of attorney and/or change of address letter.							
19.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.							
20.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).							
21.		A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).							
22.		Express Mail Label No. EV213895467US							
23.	$\boxtimes$	Other items or information:							
		Courtesy Copy of International Application							
		Eleven (11) sheets of drawings Assignees: PROSTATE DIAGNOSTICS PTY LTD of Clayton, Victoria, Australia and THE LELAND STANFORD JUNIOR UNIVERSITY, Stanford California							